Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Receiving Palbociclib: Results From the TREnd Trial.
Ilenia MigliaccioDario RomagnoliFrancesca GalardiFrancesca De LucaChiara BiagioniCurigliano GiuseppeCarmen CriscitielloAlessandro Marco MinisiniErica MorettiEmanuela RisiCristina GuarducciAgostina NardoneLaura BiganzoliMatteo BenelliLuca MalorniPublished in: JCO precision oncology (2024)
and in PI3K pathway genes at T0 were associated with worse prognosis in palbociclib-treated patients. We describe the emergence of newly acquired mutations in palbociclib-treated patients, which might potentially affect subsequent treatment.
Keyphrases
- circulating tumor
- end stage renal disease
- epidermal growth factor receptor
- newly diagnosed
- estrogen receptor
- ejection fraction
- chronic kidney disease
- clinical trial
- endothelial cells
- randomized controlled trial
- peritoneal dialysis
- single molecule
- tyrosine kinase
- circulating tumor cells
- cell free
- study protocol
- transcription factor
- genome wide
- metastatic breast cancer
- phase ii
- phase iii
- pluripotent stem cells